CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,368 | +103.1% | 113,282 | +23.0% | 0.00% | +100.0% |
| Q2 2023 | $1,658 | -5.5% | 92,093 | -15.7% | 0.00% | 0.0% |
| Q1 2023 | $1,755 | +39.3% | 109,273 | +58.7% | 0.00% | 0.0% |
| Q4 2022 | $1,260 | -99.9% | 68,843 | +36.0% | 0.00% | 0.0% |
| Q3 2022 | $994,000 | +1225.3% | 50,605 | +1152.0% | 0.00% | – |
| Q2 2022 | $75,000 | -63.9% | 4,042 | -57.4% | 0.00% | – |
| Q1 2022 | $208,000 | -93.7% | 9,486 | -91.8% | 0.00% | -100.0% |
| Q4 2021 | $3,284,000 | +809.7% | 115,574 | +574.5% | 0.00% | – |
| Q3 2021 | $361,000 | +27.6% | 17,135 | +13.8% | 0.00% | – |
| Q2 2021 | $283,000 | -24.5% | 15,061 | -38.7% | 0.00% | – |
| Q1 2021 | $375,000 | +145.1% | 24,582 | +125.4% | 0.00% | – |
| Q4 2020 | $153,000 | -31.4% | 10,908 | -23.4% | 0.00% | – |
| Q3 2020 | $223,000 | -24.4% | 14,241 | -15.2% | 0.00% | – |
| Q2 2020 | $295,000 | +446.3% | 16,788 | +358.7% | 0.00% | – |
| Q1 2020 | $54,000 | -80.8% | 3,660 | -67.3% | 0.00% | – |
| Q4 2019 | $281,000 | +212.2% | 11,198 | +87.2% | 0.00% | – |
| Q3 2019 | $90,000 | -58.3% | 5,983 | -30.7% | 0.00% | – |
| Q2 2019 | $216,000 | +78.5% | 8,633 | +62.2% | 0.00% | – |
| Q1 2019 | $121,000 | +61.3% | 5,322 | +104.1% | 0.00% | – |
| Q3 2018 | $75,000 | – | 2,608 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |